In 2017, the iwCLL program and special sessions will be organized around the following themes:

•  Emerging evidence regarding factors that contribute to the development of CLL

•  Emerging evidence regarding the diagnosis, prognosis and initial treatment of CLL

•  Emerging evidence regarding factors that contribute to the disease evolution and progression

•  Emerging evidence regarding therapy for advanced disease


Friday, May 12

7:30 am Breakfast
8:00 am – 5:00 pm Young Investigator Meeting
6:00 pm – 8:00 pm iwCLL Welcome Reception


Saturday, May 13

7:15 am Breakfast

Welcome and Introductions 

8:15 am Opening remarks
Nicholas Chiorazzi
8:30 am Reminiscences of meetings past
Kanti Rai and Jacques-Louis Binet



Session 1A         Inherited and Acquired Genetic Factors Involved in the Development of CLL
Chairs 1A: Daniel Catovsky and Stephan Stilgenbauer

9:00 am Monoclonal B-Lymphocytosis: Recent Clinical and Biologic Insights
Tait Shanafelt
9:30 am Insights Into Inherited Susceptibility to Chronic Lymphocytic Leukemia
Richard Houlston
10:00 am What is the Cell of Origin of CLL?
Olivier A. Bernard
10:30 am Morning Break
Session 1B Chairs: Emili Monsterrat and John Gribben
11:00 am Functional Evaluation of Key Recurrent Somatic Mutations in CLL
Catherine Wu
11:30 am Influences of Regulatory RNAs on CLL Development
Carlo M. Croce
Noon New Insights Revealed by Epigenetic Studies in CLL
Christopher Oakes
12:30 pm *Mutations in NOTCH1 PEST Domain Confers Growth Advantage to CLL Cells
Francesca Arruga
12:45 pm Lunch


Session 2         Role of Non-Leukemic Cells and the Microenvironment in CLL Development
Chairs: Silvia Deaglio and Christopher Pepper 

2:00 pm Molecular Aspects of Mesenchymal Stromal Cell – CLL Cell Interactions: New Targets Beyond B-cell Receptor Signaling Inhibition
Ingo Ringshausen
2:30 pm From Monocytes to Nurse-Like Cells: Myeloid Cells Matter in CLL
Martina Seiffert
3:00 pm Trafficking Between Lymphoid Microenvironments in CLL Survival and Growth
Jan A. Burger
3:30 pm Exosomes Manipulate the Microenvironment in CLL
Etienne Moussay
4:00 pm Afternoon Break
4:30 pm *CLL Mutations in the Earliest Cells of the Hematopoietic Lineage: Documentation and Need for Caution
Sonia Marsilio
4:45 pm *IL-4R – IL-4 axis Disruption by Ibrutinib Therapy Contributes to the Greater Vulnerability of U-CLL Clones to Loss of Microenvironmental Inputs
Shih-Shih Chen
5:00 pm Binet/Rai Medal Presentation
Jacques-Louis Binet and Kanti R. Rai
5:30 pm Close for the day


Sunday, May 14

Session 3         Role of the B-Cell Receptor and Other Signaling Pathways in CLL
Chairs: Nicholas Chiorazzi and Kostas Stamatopoulos

7:15 am Breakfast
8:15 am B-Cell Receptor Dependent Survival and Fitness of Normal and Malignant B Cells
Klaus Rajewsky
8:45 am Autonomous BCR Signaling in CLL
Hassan Jumaa
9:15 am From Structure to Function to Clinical Outcome: Dangerous Relationships in Autonomous B-cell Receptor Signaling in CLL
Paolo Ghia
9:45 am *Differential CLL BCR/Co-Receptor Density Regulation in Various Intraclonal Fractions, Before and During Ibrutinib Treatment
Andrea Nicola Mazzarello
10:00 am *Intraclonal Diversification and Evolution in Chronic Lymphocytic Leukemia Patients by High-Throughput Sequencing of IGHV-D-J Rearrangements
Davide Bagnara
10:15 am Morning Break
10:45 am Additional Signaling Pathways in CLL and Their Interactions With the BCR
Dimitar Efremov
11:15 am ROR1: An Orphan Becomes Apparent
Thomas J. Kipps


Chairs: Stephen Mulligan and Neil E. Kay 

Session 4         Strategies for the Evaluation and Treatment of CLL in the Front-line Setting

11:45 am Clinical Approach to the Diagnosis and Initial Evaluation of a CLL Patient
Davide Rossi
12:15 pm Presentation and discussion of revised iwCLL guidelines for the approach to a CLL patient
Michael Hallek
12:45 pm Lunch


Industry Supported Symposium jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education, and supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

1:30 pm Exploring the CLL Treatment Tool Kit: A Master Class on Modern Therapy, Clinical Trials, and Precision Medicine
4:00 pm Afternoon Break


Session 5       Additional Considerations for the Initial Treatment of CLL
Chairs: Richard Furman and Jae Park

4:30 pm Role of MRD in the Setting of the Novel Targeted Therapies
Peter Hillmen
5:00 pm *Outcomes of Ibrutinib-Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia With High-Risk Prognostic Factors in an Integrated Analysis of 3 Randomized Phase 3 Studies
Thomas J. Kipps
5:15 pm *Left Atrial Abnormality as a Predictor of Ibrutinib-Associated Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia: a Predictive Model
Anthony Mato
5:30 pm *Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) for Previously Untreated Patients With CLL With Mutated IGHV
Nitin Jain
5:45 pm *NOTCH1 Mutation as a Predictive Factor in the Context of Fludarabine and Cyclophosphamide (FC) With or Without Ofatumumab Treatment
Eugen Tausch
6:00 pm Poster Reception


Monday, May 15


Session 6         Genetic Changes Involved in the Progression and Evolution of CLL
Chairs: Christopher Vakoc and Nicole Lamanna

7:15 am  Breakfast
8:15 am On the Origin of CLL Evolution
Dan Landau
8:45 am Subclonal Architecture Before and After State-of-the-Art Treatment for CLL
Lesley Ann Sutton
9:15 am Richter’s Syndrome: Then and Now
Gianluca Gaidano
9:45 am Life after BTKi Relapse: Biology of Disease and New Strategies
John C. Byrd
10:15 am Morning Break


Industry Supported Symposium supported by AbbVie Inc.

10:45 am Evolution of Treatment in Relapsed/Refractory CLL: Past, Present, and Future
12:45 pm Lunch


Sessions 7A      Additional Therapies for the Relapsed/Refractory CLL Patient
Chairs: Michael Keating and Jacqueline Barrientos

2:00 pm *Durability of Responses on Continuous Therapy and Following Drug Cessation in Deep Responders with Venetoclax and Rituximab
Danielle Brander
2:15 pm Where Are We With PI3K Isoform Inhibitors in CLL?
Jennifer Brown
2:45 pm Anti-CD19 CAR-T Cell Therapy With Defined T-Cell Subsets for Ibrutinib-Refractory CLL
David G. Maloney


Session 7B        Additional Therapies for the Relapsed/Refractory CLL Patient
Chairs: Guillermo Dighiero and Federico Caligaris-Cappio

3:15 pm *A Novel NF-kB Inhibitor Shows Activity in Richter Syndrome
Tiziana Vaisitti
3:30 pm *Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Compatible Donors in Younger High Cytogenetic Risk CLL Patients Results in Very High Long-Term Progression-Free Survival and May Therefore Favorably Compete With Sequential Targeted Therapy
Michael van Gelder
3:45 pm *Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation for High Risk CLL Followed by Preemptive MRD-Based Immunointervention: Final Results From the Phase II ICLL03 RICAC-PMM Trial
Olivier Tournilhac
4:00 pm Closing comments
Nicholas Chiorazzi
4:15 pm Close of workshop

**Agenda subject to change
*Selected Abstract

Please contact us at for more information.